Sequenom (FRA:QNMA) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Sequenom 3-Year Revenue Growth Rate?

Sequenom's Revenue per Share for the three months ended in Jun. 2016 was €0.22.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Sequenom's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Sequenom's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequenom's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sequenom's 3-Year Revenue Growth Rate falls into.

Sequenom 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Sequenom (FRA:QNMA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Sequenom 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Sequenom's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequenom (FRA:QNMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (FRA:QNMA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sequenom.com

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Sequenom (FRA:QNMA) Headlines

No Headlines